A phase 1b (open-label)/phase 2 (randomized, double-blinded) study evaluating nab-paclitaxel and gemcitabine with or without olaratumab in first-line treatment of metastatic pancreatic cancer
Bendell, Johanna C., Pelzer, Uwe, Womack, Mark S., Borazanci, Erkut Hasan, Bahary, Nathan, Garrido-Laguna, Ignacio, Maur, Michela, Prater, Tyler, Levy, Donna Elise, Cronier, Damien, Ramage, Sam, Macarulla, Teresa
Published in Journal of clinical oncology (01.02.2018)
Published in Journal of clinical oncology (01.02.2018)
Get full text
Journal Article